专利检索_ .丝氨酸内肽酶专利检索_ .丝氨酸内肽酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
181	스트렙토키나제의 정제방법	KR1020010046671	2001-08-01	KR1020020007231A	2002-01-26	이병철
PURPOSE: A process for purifying streptokinase is provided, thereby producing the high purity of streptokinase without streptolysin, endotoxin or pyrogen. CONSTITUTION: The process for purifying streptokinase comprises the steps of: cultivating Streptococcus, removing the cell and concentrating the culture; passing it through the column packed with cation or anion exchange resins to remove impurities and streptodornase; and treating the concentrate with cholesterol to remove streptolysin, in which the concentration of cholesterol ranges from 0.0050.05%, its temperature is maintained to 35 to 47 deg.C for 10 to 20 minutes after treating the concentrate with cholesterol, and 0.05 o 0.15 mole of phosphate buffer adjusted to pH 6.0 to 8.0 is used for removing streptodornase.
182	HEAT STABLE KERATINASE AND USE THEREOF	EP14831663.1	2014-07-17	EP3027746B1	2018-10-17	HO, Meng-Chiao; WU, Shih-Hsiung; WU, Wan-Ling
A fusion gene encoding M. taiwanensis WR-220 keratinase is disclosed. The fusion comprises: (a) a first DNA sequence encoding a protein secretion signal peptide, located at the N-terminus of the fusion gene; (b) a second DNA sequence encoding an inhibitory domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the first DNA sequence; and (c) a third DNA sequence encoding a catalytic domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the second DNA sequence, wherein the fusion gene is a non-naturally occurring chimeric DNA. Also disclosed are a method for preparation of the catalytic domain of M. taiwanensis WR-220 keratinase, and use of the M. taiwanensis WR-220 keratinase.
183	YEAST CELL WALL DERIVED FLAVOUR	EP18161336.5	2018-03-12	EP3378334A1	2018-09-26	MOREL, Bernadette Theresia; VAN DEN BERG, Marco, Alexander
The present invention relates to a Method for producing a flavour composition comprising providing a composition substantially comprising disrupted yeast cell walls and contacting the composition substantially comprising disrupted yeast cell walls with a glucanase and with an endoprotease, followed by separating a liquid fraction by solid / liquid separation to provide the flavour composition. Preferred enzymes are proline specific endoprotease and laminaripentaose-producing-beta-1,3-glucanase (LPHase).
184	COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA	EP16852695.2	2016-09-30	EP3356529A2	2018-08-08	MELQUIST, Stacey; KANNER, Steven; ROZEMA, David, B.; LEWIS, David, L.; ALMEIDA, Lauren, J.; WAKEFIELD, Darren, H; TRUBETSKOY, Vladimir, S.; PEI, Tao; LI, Zhen; ALMEIDA, Aaron
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
185	PCSK9 IRNA COMPOSITIONS AND METHODS OF USE THEREOF	EP17195917.4	2013-12-05	EP3336187A1	2018-06-20	BORODOVSKY, Anna; KALLANTHOTTATHIL, Rajeev G.; FITZGERALD, Kevin; FRANK-KAMENETSKY, Maria; QUERBES, William; MAIER, Martin; CHARISSE, Klaus; KUCHIMANCHI, Satyanarayana; MANOHARAN, Muthiah; MILSTEIN, Stuart
The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
186	NUTRITIONAL COMPOSITIONS AND METHODS FOR PROMOTING COGNITIVE DEVELOPMENT	EP16732188.4	2016-06-16	EP3319460A1	2018-05-16	AO, Zihua,; BERSETH, Carol Lynn,; COBB, Patricia,; GONZALEZ, Juan M.,; LONDON, Elisha,; NGUYEN, Minhthy,; RICHARDS, James David,; RUDOLPH, Colin,; ALVEY, John D.,; MALDONADO, Yadilka,
A method for enhancing cognitive development in a pediatric subject involving administering to the subject a nutritional composition which includes up to 7 g/100 Kcal of a fat or lipid; up to 5 g/100 Kcal of a protein or protein equivalent source; 0.25 g/100 Kcal to 16 g/100 Kcal of buttermilk; 5 mg/100 Kcal to 90 mg/100 Kcal of a source of long chain polyunsaturated fatty acid; and 0.015 g/100 Kcal to 1.5 g/100 Kcal of a prebiotic.
187	COMPOSITION DE PLASMINOGÉNASE IMMOBILISÉE, PROCÉDÉ DE PRÉPARATION, UTILISATION ET DISPOSITIF COMPRENANT UNE TELLE COMPOSITION	EP16729958.5	2016-04-14	EP3283626A1	2018-02-21	REBOUL, Gérard; SAUX, Carine; OUARNE, Françoise
The invention relates to an enzymatic composition comprising: - at least one enzyme, termed plasminogenase, for converting, into plasmin, plasminogen from a blood plasma medium comprising plasminogen; - a solid support that is insoluble in aqueous solution, the solid support having dimensions suitable for being able to be retained on a filter having a cut-off threshold of less than or equal to 0.22 µm; characterized in that said plasminogenase is bound to the solid support and remains bound to this support on contact with a blood plasma medium and in that the composition is in the dry state. The invention also relates to a process for preparing such an enzymatic composition, to the use thereof and to a device (20) for preparing a blood plasma medium ex vivo rich in sterile plasmin and free of enzymatic composition.
188	PROTEASES FOR HIGH PROTEIN FERMENTED MILK PRODUCTS	EP16704523.6	2016-01-28	EP3280267A1	2018-02-14	EISELE, Thomas; BEJDER, Hans Christian; VARGAS, Enrique Guillermo D'Argence
The present disclosure provides compositions, methods, and uses concerning the enzymatic preparation of a fermented milk product.
189	METHOD	EP16704524.4	2016-01-28	EP3250040A1	2017-12-06	YU, Shukun; EISELE, Thomas; POULSEN, Charlotte Horsmans; BEJDER, Hans Christian
The present invention relates to a method of preparing a fermented milk product. The method comprises the steps of treating a milk substrate with a low pH sensitive peptidase and a microorganism, and allowing the treated milk substrate to ferment to produce the fermented milk product.
190	SERINE PROTEASES OF BACILLUS SPECIES	EP15791846.7	2015-10-27	EP3224357A1	2017-10-04	KOLKMAN, Marc; KELLETT-SMITH, Anja Hemmingsen; MEJLDAL, Rie; BABE, Lilia Maria
The present disclosure relates to serine proteases cloned from Bacillus spp., and variants thereof. Compositions containing the serine proteases are suitable for use in cleaning fabrics and hard surfaces, as well as in a variety of industrial applications.
191	MAP44 POLYPEPTIDES AND CONSTRUCTS BASED ON NATURAL ANTIBODIES AND USES THEREOF	EP15802708.6	2015-06-04	EP3151845A2	2017-04-12	HOLERS, Michael, V.; BANDA, Nirmal; KULIK, Liudmila
The present invention provides delivery methods and constructs for treating inflammatory diseases in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The antibody is used to deliver a MAp44 polypeptide or fragment thereof to sites of inflammation, where it inhibits the lectin pathway of complement activation.
192	METHOD FOR PRODUCING MICROPARTICLES	EP14837180	2014-08-20	EP3037087A4	2017-02-22	KUWATA HIDEFUMI
The present invention has an object providing microparticles having an average particle size of 100 µm or less. The present invention provides microparticles having an average particle size of 100 µm or less and a method for producing thereof. In addition, the present invention provides medicine, food and feedstuff comprising the microparticles having an average particle size of 100 µm or less.
193	MULTIPLE PROTEASES DEFICIENT FILAMENTOUS FUNGAL CELLS AND METHODS OF USE THEREOF	EP14738497.8	2014-07-10	EP3019602A2	2016-05-18	LANDOWSKI, Christopher; HUUSKONEN, Anne; WESTERHOLM-PARVINEN, Ann; SALOHEIMO, Markku; KANERVA, Anne; HILTUNEN, Jukka
The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.
194	Method of detecting ocular diseases and pathologic conditions and treatment of same	EP15155019.1	2007-12-21	EP2913341A1	2015-09-02	Zhang, Kang; Yang, Zenglin; Chen, Haoyu; Li, Dean
Ocular diseases affecting the macula or the vasculature of the eye affect a wide variety of individuals. In particular, Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the developed world and has a significant genetic predisposition. Methods of analyzing one or more mutations in the HtrA1 gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye are provided. The methods of the present invention may further include analysis of the CFH gene in order to identify individuals with a presusceptability to development of an ocular disease and a pathologic condition of the eye and diagnose those currently suffering from an ocular disease or a pathologic condition of the eye. Compositions and methods for treating ocular disease and pathologic conditions of the eye are also provided.
195	POLYPEPTIDES HAVING PROTEASE ACTIVITY	EP12748458.2	2012-08-17	EP2744900A1	2014-06-25	SJOEHOLM, Carsten; OESTERGAARD, Peter Rahbek; HOFF, Tine; PONTOPPIDAN, Katrine; OLINSKI, Robert Piotr
The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptidesin e.g. animal feed and detergents.
196	OLIGONUCLEOTIDE, AND THERAPEUTIC AGENT FOR DYSLIPIDEMIA CONTAINING OLIGONUCLEOTIDE AS ACTIVE INGREDIENT	EP11821885.8	2011-08-31	EP2612914A1	2013-07-10	OBIKA, Satoshi; IMANISHI, Takeshi; YAMAMOTO, Tsuyoshi; NARUKAWA, Keisuke; SHIBA, Mariko; YAMAOKA, Tetsuji; TORIGOE, Hidetaka; YAMASHITA, Atsushi; TACHIBANA Yoichi; KAKINOKI, Sachiro; SASAKI, Kiyomi
An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4'-position and 2'-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.
197	REDUCED-PRESSURE TREATMENT SYSTEMS AND METHODS EMPLOYING DEBRIDEMENT MECHANISMS	EP09835645.4	2009-12-17	EP2367517A2	2011-09-28	SEEGERT, Charles, Alan; WILKES, Robert, Peyton
Reduced-pressure treatment systems and methods are disclosed that employ debridement mechanisms to remove unwanted tissue. In one instance, a reduced-pressure treatment system for treating a tissue site on a patient includes a manifold member for distributing reduced pressure to the tissue site, a support member for disposing proximate the tissue site and the manifold, and a debridement mechanism coupled to the support member. The debridement mechanism is for debriding the tissue site. The system further includes a sealing drape for placing over the tissue site and manifold member. The sealing drape is operable to form a fluid seal over the tissue site and manifold member. The system also includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing drape. The system may further include a chemical-debridement subsystem. Other systems, manifolds, and methods are disclosed.
198	Processes for the preparation of glutamine-rich peptides and food preparations made therewith	EP95200641.9	1995-03-16	EP0672352B1	2002-09-25	Zuurendonk, Peter Frederik; Van de Veerdonk, Franciscus Lambertus Maria; Steijns, Johannes Maria Jozef Margaretha

199	LOCAL DELIVERY OF FIBRINOLYSIS ENHANCING AGENTS	EP95904865.3	1994-12-09	EP0732915B1	2000-08-09	DUNN, Randall, C.; HUBBELL, Jeffrey, A.; HILL-WEST, Jennifer, L.
A method of preventing adhesions by topical administration of fibrinolysis enhancing agents is described. The method uses a topically applied polymeric matrix for delivery of a fibrinolyic agent, preferably urokinase, or tPA. In the most preferred embodiment, the matrix is extremely thin and is polymerized in situ to form a biodegradable polymeric matrix. The matrix provides controlled release of the agent over a period of time effective to prevent surgical adhesions and is biodegradable, usually within the same time frame. Examples demonstrate that the combination of the matrix and the urokinase or tPA is effective in preventing surgical adhesions.
200	VERFAHREN ZUR HERSTELLUNG VON WEIZENPROTEINHYDROLYSATEN	EP96901272.3	1996-01-16	EP0805631B1	1999-05-06	VON KRIES, Edith; HEILEMANN, Andrea; SANDER, Andreas
The proposal is for an improved process for producing wheat protein hydrolysates in which protein-containing basic substances are first hydrolysed in with proteinases and then with peptidases. The resultant hydrolysates are particularly suitable for producing light-coloured condensation products with fatty acids with a long shelf life.

5 6 7 8 9 10 11 12 13 14

该功能需要专业版企业版VIP权限，您可以：